Leishmaniasis malady

MedlinePlus: Leishmaniasis is a parasitic disease spread by the bite of infected sand flies. there are several different forms of leishmaniasis. the most common are cutaneous and visceral. the cutaneous type causes skin sores. the visceral type affects internal organs such as the spleen, liver and bone marrow. people with this form usually have fever, weight loss and an enlarged spleen and liver. leishmaniasis is found in parts of about 88 countries. most of these countries are in the tropics and subtropics. it is possible but very unlikely that you would get this disease in the united states. but you should be aware of it if you are traveling to the middle east or parts of central america, south america, asia, africa or southern europe. the best way to prevent the disease is to protect yourself from sand fly bites. if not treated, leishmaniasis can be serious. visceral disease can be deadly. centers for disease control and prevention²³

MalaCards: Leishmaniasis, also known as leishmaniasis, unspecified (disorder), is related to visceral leishmaniasis and cutaneous leishmaniasis. An important gene associated with Leishmaniasis is KAZA (Kala-azar (visceral leishmaniasis), susceptibility to), and among its related pathways are Jak-STAT signaling pathway and Akt Signaling. The drugs itraconazole and ketoconazole and the compounds thyroxine and vitamin a have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, whole blood and spleen, and related mouse phenotypes are endocrine/exocrine gland and respiratory system.

Disease Ontology: A parasitic protozoa infectious disease that involves infection caused by protozoan parasite of the genus leishmania, which is transmitted by the bite of sand fly (subfamily phlebotominae).⁶

NIH Rare Diseases: Leishmaniasis is a parasitic disease spread by the bite of infected sand flies. There are several different forms of leishmaniasis. The most common are cutaneous and visceral. The cutaneous type causes skin sores. The visceral type affects internal organs such as the spleen, liver and bone marrow. People with this form usually have fever, weight loss, and an enlarged spleen and liver. Visceral disease can be deadly without proper treatment. Leishmaniasis is found in parts of the Middle East, Central America, South American, Asia, Africa, and southern Europe. Most of these countries are in the tropics and subtropics. It is possible but very unlikely to get this disease in the United States.³⁰

CDC: Leishmaniasis includes two major diseases, cutaneous leishmaniasis and visceral leishmaniasis, caused by more than 20 different leishmanial species.²

Wikipedia: Leishmaniasis is a disease caused by protozoan parasites that belong to the genus Leishmania and is...⁴⁴ more...

Aliases & Descriptions:

leishmaniasis 6 30 8 32 23 43 leishmaniasis, unspecified (disorder) 6 cutaneous leishmaniasis (subtype) 30 visceral leishmaniasis (subtype) 30 leishmaniasis nos (disorder) 6

leishmaniasis, unspecified 6 leishmaniasis (disorder) 6 kala-azar 30

Diseases related to leishmaniasis by text searches and GeneDecks gene sharing:

(show top 50)    (show all 847)

id	Related Disease	Score	Top Affiliating Genes
1	visceral leishmaniasis	39.3	LMLN, IL10, IL4, IFNG, LTA, DPEP1
2	cutaneous leishmaniasis	39.0	LMLN, MT-CYB, CD209, FCER2, IL10, IL13
3	mucocutaneous leishmaniasis	34.8	ENTPD3, ENTPD8, IFNG, TNF, RPL14, PKD2L1
4	syphilis	32.2	CD209, CD4, CCR5, IGHV4-39, IGHE, HLA-DRB1
5	leptospirosis	31.8	PIK3C2A, IL10, IL12B, IL15, IL1A, IL1B
6	rheumatoid arthritis	31.0	MBL2, HLA-DRB1, TNFRSF1A, CRP, LTA
7	arthritis	30.7	IL17A, IL1A, IL1B, IL6, IL8, TNF
8	tuberculosis	29.8	CD209, IL10, IL12B, IL1B, IL4, MBL2
9	onchocerciasis	29.6	MPI, IL10, IL13, IL4, IL5, IGHE
10	immunodeficiency	29.4	MYD88, BMP6, CIITA, SAG, CD209, CD28
11	leprosy	28.9	IL10, HLA-DQA1, HLA-DQB1, HLA-DRB1, CR1, LTA
12	sleeping sickness	28.9	GSR, APOA1, SRM, ODC1, TF, PGD
13	acquired immunodeficiency syndrome	28.6	CIITA, CD4, ITGAM, FCER2, FCGR3A, IL10
14	malaria	28.6	IL10, IL1A, IL4, IL4R, IFNG, IFNGR2
15	psoriatic arthritis	28.3	IRAK1, IL10, IL1B, IL6, TNF, LTA
16	spondylitis	26.1	RELA, BMP6, JAK2, GSR, IL10, IL12B
17	toxoplasmosis	25.7	RELA, MYD88, CIITA, SAG, JAK1, JAK2
18	acute lymphoblastic leukemia	25.1	JUN, JAK1, JAK2, ITGA4, ITGAM, ITGB1
19	glomerulonephritis	24.2	LPA, BMP6, CD28, CDKN3, ITGA4, ITGB1
20	chagas disease	24.2	RELA, MYD88, MT-CYB, JUN, CD28, CD8A
21	trypanosomiasis	21.9	RELA, MYD88, BMP6, JUN, FOS, IRAK1
22	diabetes mellitus	21.1	PIK3C2A, LPA, BMP6, CIITA, JUN, CD28
23	lymphoblastic leukemia	20.9	RELA, BMP6, JUN, JAK1, JAK2, CD28
24	kaposi's sarcoma	20.8	PIK3C2A, RELA, JUN, JAK2, CD209, CD28
25	lupus erythematosus	20.1	PIK3C2A, NCF2, LPA, MYD88, BMP6, CIITA
26	sarcoma	19.7	PIK3C2A, RELA, BMP6, JUN, JAK1, JAK2
27	leukemia	18.1	PIK3C2A, NCF2, NCF4, RELA, LMLN, MYD88
28	graft versus host disease	14.7	CD28, IL10, IL13, IL15, IL2, IL2RA
29	cholangitis	14.6	CD28, IL10, IL17A, IL2, IL21, IL4
30	primary sclerosing cholangitis	14.6	CD28, IL10, IL2, IL21, IL4, IL6
31	sclerosing cholangitis	14.6	CD28, IL10, IL2, IL21, IL4, IL6
32	omenn syndrome	14.5	IL10, IL4, IL5, IGHE, IFNG, IFNGR1
33	vulvovaginitis	14.5	IL10, IL13, IL4, IL5, MBL2, IGHE
34	hypothyroidism	14.5	PIK3C2A, LPA, FOS, GSR, IL10, IL13
35	pulmonary tuberculosis	14.5	IL10, IL12B, IL12RB1, IL2, IL2RA, IL4
36	acute graft versus host disease	14.5	IL10, IL15, IL2, IL2RA, IL2RB, IL4
37	allergic rhinitis	14.5	FCER2, IL13, IL4, IL4R, IL5, IL8
38	food allergy	14.5	FOXP3, FCER2, IL10, IL13, IL4, IL4R
39	fasciitis	14.5	PIK3C2A, BMP6, IL10, IL5, GPT, IGHE
40	alpha 1-antitrypsin deficiency	14.5	BMP6, IL10, IL8, CCL2, IGHE, IFNG
41	posterior uveitis	14.5	SAG, IL2RA, IL2RB, FASLG, FAS, IGHE
42	twinning	14.5	MT-CYB, FOXP3, FH, IL10, IL12B, IL1A
43	echinococcosis	14.4	CD8A, IL10, IL12B, IL2RA, IL4, IL5
44	bilirubin metabolic disorder	14.4	IL6, APOA1, APOE, GPT, IGFBP3, IGF1
45	trachoma	14.4	FOXP3, IL10, IL17A, IL4, MBL2, MAPK1
46	sickle cell anemia	14.4	RELA, BMP6, IL13, IL4R, IL8, MBL2
47	eosinophilic esophagitis	14.4	IL10, IL13, IL5, IGHE, IFNG, HLA-DQA1
48	primary biliary cirrhosis	14.4	CIITA, FOXP3, IL2RB, MBL2, GPT, ALB
49	hyperparathyroidism	14.4	IL10, IL10RA, IL12RB1, IL2, IL2RA, IL2RB
50	pulmonary eosinophilia	14.4	IL13, IL4, IL5, IL8, IGHE, IFNG

Approved drugs:

Drug clinical trials:

Inferred drug relations via UMLS/NDF-RT:

^43 28 itraconazole, ketoconazole

MalaCards organs/tissues related to leishmaniasis:

²²

MGI Mouse Phenotypes related to leishmaniasis:

²⁵ (show all 23)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	endocrine/exocrine gland phenotype	MP:0005379	11.1	HSPA2, GGT1, CSN2, DPP4, TLR2, LTA
2	respiratory system phenotype	MP:0005388	10.7	CALCA, GPR132, APOE, IL12B, IL12A, VDAC3
3	hematopoietic system phenotype	MP:0005397	10.5	HLA-DOA, CXCR2, NFKBIB, PNP, DLK1, PTPN6
4	liver/biliary system phenotype	MP:0005370	10.1	CCR5, MAPK11, MAP3K7, APOA1, IL6, IL2
5	renal/urinary system phenotype	MP:0005367	9.7	PNP, TGFB2, CXCR2, CXCR4, OCA2, C3
6	other phenotype	MP:0005395	9.6	NOS2, ABCB1, ABCB7, TLR2, CSN2, DLK1
7	embryogenesis phenotype	MP:0005380	9.2	AMD1, CALR, TNFRSF1A, ODC1, ABCB7, G6PD
8	integument phenotype	MP:0010771	9.2	ITGB2, FOS, FOXP3, IL13, IL2RB, IL4
9	digestive/alimentary phenotype	MP:0005381	9.1	STAT1, TGFB3, TGFB2, TGFB1, TLR2, NOS2
10	reproductive system phenotype	MP:0005389	9.0	C3, CSN2, OCA2, VDAC3, MARCKSL1, FASLG
11	immune system phenotype	MP:0005387	8.8	NCF4, TNF, TPI1, HLA-DQB1, HLA-DQA1, GNB1L
12	nervous system phenotype	MP:0003631	8.3	FLI1, FOS, ITGB1, ITGAM, CD4, CD8A
13	normal phenotype	MP:0002873	8.2	CTLA4, TPI1, TXNRD1, HLA-DQB1, ALB, IFNG
14	muscle phenotype	MP:0005369	7.6	TLR2, NFKB1, NOS2, DLK1, PTGS2, TNFRSF1A
15	tumorigenesis	MP:0002006	7.6	CAT, ICAM1, IFNGR1, IFNG, IFNB1, IGF1
16	mortality/aging	MP:0010768	7.6	CCL2, ABCB1, LTA, NFKBIB, NFKBIA, NOS2
17	behavior/neurological phenotype	MP:0005386	7.3	NFKB1, NOS2, CYBA, PTPN1, TNFRSF1A, TXNRD1
18	vision/eye phenotype	MP:0005391	7.2	TLR4, LTA, NOS2, DLK1, PTGS2, TNFRSF1A
19	growth/size phenotype	MP:0005378	7.1	JAK2, JAK1, JUN, MPI, BMP6, VDAC3
20	skeleton phenotype	MP:0005390	6.3	NFKB1, CTLA4, DLK1, PTPN6, PTPN1, PTGS2
21	cardiovascular system phenotype	MP:0005385	5.5	GSR, CALCA, CALR, ICAM1, F5, IFNGR1
22	homeostasis/metabolism phenotype	MP:0005376	5.5	IL21, IL1A, IL13, IL12A, IL10RA, FCGR3A
23	cellular phenotype	MP:0005384	5.3	NOS2, ADA, C3, TLR4, TLR2, G6PD

Articles related to leishmaniasis:

(show top 50)    (show all 253)

id	Title	Authors	Year	Affiliating Genes
1	CD 28 gene polymorphism and plasma concentration of s oluble CD 28 in Iranian patients with visceral leishmaniasis. (20962715)	Hashemi S.H.... Naghili B.	2010	CD28
2	Quantification of parasite load in clinical samples o f leishmaniasis patients: IL-10 level correlates with parasite load in visceral leishmaniasis. (20404924)	Verma S.... Salotra P.	2010	IL10
3	Enhanced lesional Foxp3 expression and peripheral ane rgic lymphocytes indicate a role for regulatory T cells in Indian post-kala-aza r dermal leishmaniasis. (20032994)	Ganguly S.... Chatterjee M.	2010	FOXP3
4	In leishmaniasis due to Leishmania guyanensis infection, distinct intralesional interleukin-10 and Foxp3 mRNA expression are associated with unresponsiveness to treatment. (19125672)	Bourreau E.... Launois P.	2009	IL10, FOXP3
5	Disease-associated glycosylated molecular variants of human C-reactive protein activate complement-mediated hemolysis of erythrocyte s in tuberculosis and Indian visceral leishmaniasis. (19499327)	Ansar W.... Mandal C.	2009	CRP
6	Leishmania donovani vs immunity: T-cells sensitized from Leishmania of one donor may modulate their cytokines pattern on re-stimulation with Leishmania from different donor in visceral leishmaniasis. (18948098)	Narayan S.... Das P.	2009	IFNG
7	Increased levels of interleukin-10 and IgG3 are hallmarks of Indian post-kala-azar dermal leishmaniasis. (18444882)	Ganguly S.... Chatterjee M.	2008	IL10
8	Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients. (17395340)	Rafati S.... Soong L.	2007	HSPA4
9	Elevated levels of soluble non-classical major histocompatibility class I molecule human leucocyte antigen (HLA)-G in the blood of HIV-infected patients with or without visceral leishmaniasis. (17223963)	Donaghy L.... Gangneux J.P.	2007	HLA-G
10	Albumin-quercetin combination offers a therapeutic advantage in the prevention of reduced survival of erythrocytes in visceral leishmaniasis. (17644434)	sen G.... Biswas T.	2007	ALB
11	Inducible nitric oxide synthase and cytokine pattern in lesions of patients with American cutaneous leishmaniasis. (16309499)	DA-az N.L.... Tapia F.J.	2006	IL10
12	Mixed inflammatory/regulatory cytokine profile marked by simultaneous raise of interferon-gamma and interleukin-10 and low frequency of tumour necrosis factor-alpha(+) monocytes are hallmarks of active human visceral Leishmaniasis due to Leishmania chagasi infection. (16968407)	Peruhype-MagalhALes V.... Correa-Oliveira R.	2006	IFNG, IL10
13	Pathophysiology of visceral leishmaniasis - some recent concepts. (16778309)	Malla N.... Mahajan R.C.	2006	BMP6
14	Localized cutaneous leishmaniasis due to Leishmania donovani and Leishmania tropica: preliminary findings of the study of 161 new cases from a new endemic focus in himachal pradesh, India. (15964970)	Sharma N.L.... Sharma R.C.	2005	LMLN
15	Functional status of haemostasis system in patients with visceral leishmaniasis (16369067)	Lomtadze M.L.... Dzhokhtaberidze T.G.	2005	PROC
16	Proteomic approach for characterization of immunodominant membrane-associated 30- to 36-kiloDalton fraction antigens of Leishmania infantum promastigotes, reacting with sera from Mediterranean visceral leishmaniasis patients. (15699427)	Kamoun-Essghaier S.... Dellagi K.	2005	UQCRFS1, GNB1L
17	Expression of inducible nitric oxide synthase in human cutaneous leishmaniasis. (16311916)	Serarslan G.... Atik E.	2005	NOS2
18	Evaluation of In Vitro Production of IFN-gamma, IL-10, IL-12 and IL-13 by Blood Cells in Patients with Cutaneous Leishmaniasis Lesions. (17301418)	Mahmoodi M.... Esfandiarpour I.	2005	IFNG, IL10, IL13
19	Elevated plasma levels of interferon (IFN)-gamma, IFN-gamma inducing cytokines, and IFN-gamma inducible CXC chemokines in visceral leishmaniasis. (15569785)	Hailu A.... Kager P.A.	2004	IFNG, CXCL9
20	Increased expression of HIV co-receptor CXCR4 on CD4+ T-cells in patients with active visceral leishmaniasis. (15000561)	Hailu A.... van der Poll T.	2004	CXCR4
21	Anti-desmoglein-1 antibodies in onchocerciasis, leishmaniasis and Chagas disease suggest a possible etiological link to Fogo selvagem. (15610512)	Diaz L.A.... Rivitti E.A.	2004	DSG1
22	Detection of iNOS gene expression in cutaneous leishmaniasis biopsy tissue. (11985871)	Arevalo I.... Matlashewski G.	2002	NOS2
23	Perspectives for new drugs against trypanosomiasis and leishmaniasis. (11966468)	Barrett M.P.... Gilbert I.H.	2002	PGD
24	Severe hypocholesterolemia with reduced serum lipoprotein(a) in a patient with visceral leishmaniasis. (12175095)	Liberopoulos E.... Elisaf M.	2002	APOE, APOA1
25	IgG anti-IgE autoantibodies in visceral leishmaniasis. (11992157)	Atta A.M.... Carvalho E.M.	2002	IGHE
26	Tissue cytokine responses in canine visceral leishmaniasis. (11294678)	Quinnell R.J.... Kaye P.M.	2001	IL10
27	Unresponsiveness of specific T cells to IL-12 is associated with active cutaneous leishmaniasis owing to Leishmania guyanensis. (11555399)	Bourreau E.... Launois P.	2001	IL13
28	Interleukin (IL)-13 is the predominant Th2 cytokine in localized cutaneous leishmaniasis lesions and renders specific CD4+ T cells unresponsive to IL-12. (11237813)	Bourreau E.... Launois P.	2001	IL13
29	High levels of C-reactive protein in the peripheral blood during visceral leishmaniasis predict subsequent development of post kala-azar dermal leishmaniasis. (10708005)	Gasim S.... Elhassan A.M.	2000	IL10
30	A novel Leishmania infantum recombinant antigen which elicits interleukin 10 production by peripheral blood mononuclear cells of patients with visceral leishmaniasis. (10639426)	Suffia I.... Kubar J.	2000	IL10
31	IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis. (10930301)	Bacellar O.... Carvalho E.M.	2000	IFNG, IL10
32	Treatment of two patients with diffuse cutaneous leishmaniasis caused by Leishmania mexicana modifies the immunohistological profile but not the disease outcome. (10632987)	Salaiza-Suazo N.... Becker I.	1999	IFNG
33	T-cell response in human leishmaniasis. (10065635)	Kharazmi A.... Kemp M.	1999	IL4, IFNG, IL10
34	Leishmania pifanoi amastigote antigen P-4: epitopes involved in T-cell responsiveness in human cutaneous leishmaniasis. (9632572)	Haberer J.E.... Coutinho S.G.	1998	PAGE4
35	High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis. (9472662)	Gasim S.... Theander T.G.	1998	IL10
36	Adenosine deaminase activities in sera, lymphocytes and granulocytes in patients with cutaneous leishmaniasis. (9711339)	Erel O.... Ozdemir Y.	1998	ADA
37	Alterations of serum selenium, zinc, copper, and iron concentrations and some related antioxidant enzyme activities in patients with cutaneous leishmaniasis. (9892499)	Kocyigit A.... Aktepe N.	1998	SOD1, TF, CAT
38	Presence of circulating levels of interferon-gamma, interleukin-10 and tumor necrosis factor-alpha in patients with visceral leishmaniasis. (9713135)	de Medeiros I.M.... SalomALo R.	1998	IFNG, IL10
39	Leishmania aethiopica derived from diffuse leishmaniasis patients preferentially induce mRNA for interleukin-10 while those from localized leishmaniasis patients induce interferon-gamma. (9041358)	Akuffo H.... Bakhiet M.	1997	IFNG, IL10
40	Animal reservoirs of leishmaniasis in Marigat, Baringo District, Kenya. (8625862)	Githure J.I.... Koech D.K.	1996	GPI, PGD, MDH2
41	Characterization of the immune response in subjects with self-healing cutaneous leishmaniasis. (7573712)	Carvalho E.M.... Rocha H.	1995	IFNG
42	Diabetes mellitus associated with pentamidine isethio nate in diffuse cutaneous leishmaniasis. (8668842)	Costa J.M.... Burattini M.N.	1995	IFNG
43	Tumor necrosis factor alpha (TNF-alpha) and TNF-beta and their receptors in experimental cutaneous leishmaniasis. (8132347)	de Kossodo S.... MA1ller I.	1994	LTA
44	Dichotomy of the human T cell response to Leishmania antigens. II. Absent or Th2-like response to gp63 and Th1-like response to lipophosphoglycan-associated protein in cells from cured visceral leishmaniasis patients. (8004810)	Kurtzhals J.A.... Theander T.G.	1994	LMLN
45	CD23 and IgE expression during the human immune response to cutaneous leishmaniasis: possible role in monocyte activation. (8008965)	Vouldoukis I.... Tselentis Y.	1994	FCER2
46	Treatment of atypical leishmaniasis with interferon gamma resulting in progression of Kaposi's sarcoma in an AIDS patient. (7711412)	Albrecht H.... Mensing H.	1994	IFNG
47	Hepatotoxicity of sodium stibogluconate therapy for American cutaneous leishmaniasis. (7570843)	Hepburn N.C.... Hayes P.C.	1994	GPT
48	Persistence of virulent Leishmania major in murine cu taneous leishmaniasis: a possible hazard for the host. (8093358)	Aebischer T.... Handman E.	1993	LMLN
49	Cytokine patterns in the pathogenesis of human leishmaniasis. (8473490)	Pirmez C.... Modlin R.L.	1993	IL2, IL4, IFNG
50	Production of interferon gamma in cultures of whole blood obtained in the course of and after healing of cutaneous leishmaniasis. (1796880)	Frankenburg S.... Klaus S.	1991	IFNG

Genes related to leishmaniasis according to GeneCards:

(show top 50)    (show all 205)

id	Symbol	Description	Score	GeneCards Section Context
1	KAZA	Kala-azar (visceral leishmaniasis), susceptibility to	11.0	Aliases & Descriptions
2	IFNG	interferon, gamma	11.0	Publications, Pathways & Interactions
3	IL10	interleukin 10	11.0	Publications, Pathways & Interactions
4	LMLN	leishmanolysin-like (metallopeptidase M8 family)	11.0	Publications
5	IL4	interleukin 4	11.0	Pathways & Interactions, Publications
6	PGD	phosphogluconate dehydrogenase	11.0	Publications
7	SLC11A1	solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1	11.0	Publications
8	IL13	interleukin 13	11.0	Publications
9	PKD2L1	polycystic kidney disease 2-like 1	11.0
10	LTA	lymphotoxin alpha (TNF superfamily, member 1)	11.0	Publications
11	HSPA4	heat shock 70kDa protein 4	11.0	Publications
12	IL5	interleukin 5 (colony-stimulating factor, eosinophil)	11.0	Publications
13	TNF	tumor necrosis factor	11.0	Publications, Pathways & Interactions
14	MPI	mannose phosphate isomerase	11.0	Publications
15	CSN2	casein beta	11.0	Publications
16	MDH2	malate dehydrogenase 2, NAD (mitochondrial)	11.0	Publications
17	MT-CYB	mitochondrially encoded cytochrome b	11.0	Publications
18	GPI	glucose-6-phosphate isomerase	11.0	Publications
19	IFNGR1	interferon gamma receptor 1	11.0	Publications, Pathways & Interactions
20	FOXP3	forkhead box P3	11.0	Publications
21	FCER2	Fc fragment of IgE, low affinity II, receptor for (CD23)	11.0	Publications
22	MON2	MON2 homolog (S. cerevisiae)	11.0
23	ADA	adenosine deaminase	11.0	Publications
24	G6PD	glucose-6-phosphate dehydrogenase	11.0	Publications
25	CST3	cystatin C	11.0	Publications
26	HLA-DQB1	major histocompatibility complex, class II, DQ beta 1	11.0	Publications, Pathways & Interactions
27	CP	ceruloplasmin (ferroxidase)	11.0	Publications
28	ICAM1	intercellular adhesion molecule 1	11.0	Publications
29	IGHE	immunoglobulin heavy constant epsilon	11.0	Publications
30	IL2RA	interleukin 2 receptor, alpha	11.0	Publications
31	NOS2	nitric oxide synthase 2, inducible	11.0	Publications, Pathways & Interactions
32	BMP6	bone morphogenetic protein 6	11.0	Publications
33	IL8	interleukin 8	11.0	Publications
34	PAGE4	P antigen family, member 4 (prostate associated)	11.0	Publications
35	IFN1@	interferon, type 1, cluster	11.0	Publications
36	CCL16	chemokine (C-C motif) ligand 16	11.0	Publications
37	KRT39	keratin 39	11.0
38	IL27	interleukin 27	11.0	Publications
39	SRM	spermidine synthase	11.0	Publications
40	HSPA2	heat shock 70kDa protein 2	11.0	Publications
41	CCL1	chemokine (C-C motif) ligand 1	11.0	Publications
42	GNB1L	guanine nucleotide binding protein (G protein), beta polypeptide 1-like	11.0	Publications
43	VDAC3	voltage-dependent anion channel 3	11.0	Publications
44	UQCRFS1	ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1	11.0	Publications
45	HSPA1L	heat shock 70kDa protein 1-like	11.0	Publications
46	DLK1	delta-like 1 homolog (Drosophila)	11.0	Publications
47	GZMA	granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3)	11.0	Publications
48	HABP2	hyaluronan binding protein 2	11.0	Publications
49	IL10RA	interleukin 10 receptor, alpha	11.0	Publications
50	TPI1	triosephosphate isomerase 1	11.0	Publications

Pathways related to leishmaniasis according to GeneDecks:

(show top 50)    (show all 322)

id	Pathway	Score	Top Affiliating Genes
1	Jak-STAT signaling pathway20	10.6	JAK1, JAK2, IL10, IL10RA, IL12A, IL12B
2	Akt Signaling36	10.6	CD28, CD4, ITGAM, ITGB2, IL10, IL10RA
3	Immune response_ICOS pathway in T-helper cell41	10.6	HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1
4	THC Differentiation Pathway36	10.5	CD28, IL10, IL10RA, IL12A, IL12B, IL12RB1
5	Allograft rejection20	10.3	CD28, IL10, IL12A, IL12B, IL2, IL4
6	G-protein signaling N-RAS regulation pathway10	10.2	CD4, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1
7	CTLA4 Signaling36	10.1	CD28, CD8A, CD4, HLA-DMA, HLA-DMB, HLA-DOA
8	Graft-versus-host disease20	10.1	CD28, IL1A, IL2, FASLG, HLA-DMA, HLA-DMB
9	IL-2 Signaling and its Primary Biological Effects in Different Immune Cell Types37	10.1	FOXP3, IL10, IL12A, IL2, IL2RA, IL2RB
10	Endothelin-1 Signaling Pathway36	10.1	BMP6, IL10, IL12A, IL12B, IL13, IL1A
11	all-trans-Retinoic Acid Signaling in Brain36	10.1	BMP6, IL10, IL12A, IL12B, IL13, IL15
12	Immune response Antigen presentation by MHC class II10	10.0	CD4, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1
13	Immune response_Antigen presentation by MHC class II41	10.0	CD4, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1
14	Immune response NFAT in immune response10	10.0	RELA, CD28, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB
15	Systemic lupus erythematosus20	9.9	CD28, FCGR1A, FCGR2A, FCGR2C, FCGR3A, FCGR3B
16	ICos-ICosL Pathway in T-Helper Cell36	9.8	PIK3C2A, CD28, CD4, IL2, IL2RA, IL2RB
17	IL-21 Signaling and its Primary Biological Effects in Different Immune Cell Types37	9.7	IL12B, IL17A, IL1B, IL21, IL4, IL4R
18	Type I diabetes mellitus20	9.6	CD28, IL12A, IL12B, IL1A, IL1B, IL2
19	Malaria20	9.5	MYD88, ITGB2, IL10, IL12A, IL1B, IL6
20	Cytokine production by Th17 cells in CF41	9.2	RELA, MYD88, JAK1, JAK2, IL12B, IL12RB1
21	STAT3 Pathway36	9.1	BMP6, JAK2, CD28, CD4, IL10, IL10RA
22	Immune response T cell receptor signaling pathway10	9.1	RELA, CD4, MAPK3, HLA-DMA, HLA-DMB, HLA-DOA
23	IL-10 Pathway36	8.9	JAK1, IL10, IL10RA, IL1A, IL1B, IL6
24	Hematopoietic cell lineage20	8.9	CD8A, CD4, ITGA4, ITGAM, FCER2, FCGR1A
25	IL-1 beta-dependent CFTR expression41	8.8	RELA, MYD88, IRAK1, IRAK4, IL1B, MAP3K7
26	Regulation of eIF4 and p70S6K36	8.8	CD4, ITGA4, ITGAM, ITGB1, ITGB2, IL12A
27	NF-KappaB (p50-p65) Pathway36	8.6	RELA, MYD88, BMP6, IRAK1, IRAK4, IL1A
28	NF-KappaB Family Pathway36	8.5	RELA, MYD88, BMP6, IRAK1, IRAK4, IL1A
29	ERK Signaling36	8.5	BMP6, ITGA4, ITGAM, ITGB1, ITGB2, IL10
30	Colorectal Cancer Metastasis36	8.5	JAK1, MMP9, MLC1, IL6, MAPK3, MAPK1
31	Immune response MIF-mediated glucocorticoid regulation10	8.4	RELA, JUN, FOS, IL2, IL6, IL8
32	Immune response_TLR signaling pathways41	8.4	RELA, MYD88, JUN, IRAK1, IRAK4, IL4
33	Immune response_MIF-mediated glucocorticoid regulation41	8.4	RELA, JUN, FOS, IL2, IL6, IL8
34	Immune response IL-12-induced IFN-gamma production10	8.3	RELA, JUN, JAK2, IRAK1, IL12A, IL12B
35	NF-kappaB Signaling3	8.3	RELA, MYD88, IRAK1, IRAK4, IL1B, FAS
36	RANK Signaling in Osteoclasts36	8.3	JUN, FOS, MAP3K7, MAPK12, MAPK13, MAPK3
37	IL-2 Pathway36	8.2	JUN, JAK1, FOS, IL2, IL2RA, IL2RB
38	Mucin expression in CF via IL-6, IL-17 signaling pathways41	8.2	RELA, JUN, JAK2, FOS, IL17A, IL6
39	Rheumatoid arthritis20	8.1	ATP6V0B, JUN, CD28, ITGB2, FOS, IL15
40	CDC42 Pathway36	8.0	JUN, ITGA4, ITGAM, ITGB1, ITGB2, FOS
41	T cell receptor signaling pathway20	7.9	RELA, JUN, CD28, CD8A, CD4, FOS
42	Antioxidant Action of Vitamin-C36	7.6	NCF1, NCF2, NCF4, BMP6, JUN, JAK2
43	HMGB1 Pathway36	7.6	JUN, FOS, IL1A, IL1B, MAPK12, MAPK13
44	Mucin expression in CF via TLRs, EGFR signaling pathways41	7.5	RELA, MYD88, JUN, FOS, IRAK1, IRAK4
45	NFAT in Immune Response36	7.4	BMP6, JUN, CD28, CD4, FOS, FCER2
46	Immune response_MIF in innate immunity response41	6.9	RELA, MYD88, JUN, IRAK1, IRAK4, IL1B
47	Toll-like receptor signaling pathway20	6.7	RELA, MYD88, JUN, FOS, IRAK1, IRAK4
48	MAPK signaling pathway20	6.6	RELA, JUN, FOS, IL1A, IL1B, FASLG
49	Immune response_IL-1 signaling pathway41	6.5	RELA, MYD88, JUN, FOS, IRAK1, IRAK4
50	Tuberculosis20	5.9	RELA, MYD88, CIITA, ATP6V0B, JAK1, JAK2

Compounds related to leishmaniasis according to GeneDecks:

(show top 50)    (show all 434)

id	Compound	Score	Top Affiliating Genes
1	thyroxine32 18	12.3	PIK3C2A, LPA, CIITA, FOS, GSR, IL10
2	vitamin a32 9 18 9	13.8	SAG, GSR, APOE, FAS, GPT, IGFBP3
3	aspartate32	10.6	PIK3C2A, BMP6, MT-CYB, SAG, MPI, ITGA4
4	tacrolimus32 34 9 9	13.6	BMP6, CD28, CDKN3, ITGA4, IL10, IL13
5	rituximab32 34 9 9	13.5	FCGR1A, FCGR2A, FCGR2C, FCGR3A, FCGR3B, IL10
6	chloroquine32 34 9 9	13.5	BMP6, CIITA, CD4, ITGAM, GSR, IL10
7	histamine32 18	11.4	BMP6, ITGAM, ITGB2, FCER2, FCGR2A, IL10
8	hydrocortisone32 9 9	12.3	BMP6, FCER2, IL10, IL13, IL15, IL1A
9	2,5-oligoadenylate32	10.2	IL10, IL2, IL2RA, IL2RB, IL6, GPT
10	doxorubicin32 34 9 9	13.2	PIK3C2A, BMP6, GSR, FCGR1A, IL13, IL2RA
11	prednisolone32 9 9	12.2	PIK3C2A, BMP6, CDKN3, ITGAM, ITGB2, FCGR1A
12	infliximab32 9 9	12.2	ITGA4, IL10, IL15, IL17A, IL1B, IL2RA
13	rapamycin32 42	11.1	JAK2, FOXP3, IL2, IL2RB, CCR5, IFNG
14	lactate32	10.1	PIK3C2A, BMP6, CDKN3, ITGAM, ITGB2, MMP9
15	methotrexate32 34 42 9 9	14.1	PIK3C2A, BMP6, MMP9, GSR, FCGR3A, IL10
16	il 1032	10.1	BMP6, CD8A, IL10, IL10RA, IL12B, IL13
17	mannose32	9.9	CIITA, MPI, CD209, CD4, ITGAM, MLC1
18	fibrinogen32	9.9	PIK3C2A, LPA, ITGAM, ITGB1, ITGB2, FCGR1A
19	arginine32	9.7	PIK3C2A, LPA, ITGB2, ARG1, GSR, FCGR2A
20	groalpha32	9.7	IL10, IL13, IL17A, IL1A, IL1B, MAPK14
21	aspirin32 34 18	11.6	LPA, BMP6, JAK2, ITGAM, IL13, IL2RA
22	lipoteichoic acid32	9.6	MYD88, IRAK1, IL10, IL12B, IL1B, IL6
23	epinephrine32 9 18 9	12.5	PIK3C2A, BMP6, JAK2, ITGAM, MMP9, GSR
24	poly(i-c)32	9.3	IL12B, IL15, IL1B, IL4, IL5, IL6
25	heparin32 9 18 9	12.3	PIK3C2A, LPA, SAG, CD4, ITGA4, ITGAM
26	testosterone32 9 18 9	12.2	PIK3C2A, RELA, MMP9, IL1A, IL2RA, IL5
27	adenylate32	9.2	SAG, CDKN3, ITGAM, ITGB2, MMP9, FOS
28	leukotriene b432 42 18	11.0	ITGAM, ITGB2, MMP9, FCER2, FCGR3B, IL13
29	calcitriol32 42 9 18 9	13.0	BMP6, JUN, ITGAM, ITGB1, FOS, FCER2
30	n acetylcysteine32	8.9	JAK1, JAK2, ITGAM, MMP9, FOS, IL2RA
31	sb 20358032 42	9.9	BMP6, ITGAM, ITGB1, ITGB2, MMP9, FOS
32	cysteine32	8.8	LPA, LMLN, CD4, ITGAM, ITGB1, MMP9
33	silymarin32	8.7	BMP6, JUN, MMP9, GSR, MAPK1, GPT
34	glutamate32	8.6	BMP6, JAK2, CD4, CDKN3, ITGB2, MMP9
35	alanine32	8.5	PIK3C2A, BMP6, CIITA, MT-CYB, SAG, JAK1
36	cisplatin32 34 9 9	11.4	PIK3C2A, BMP6, JAK2, CDKN3, GSR, IL2
37	fmlp32	8.0	NCF2, NCF4, MT-CYB, ITGA4, ITGAM, ITGB1
38	indomethacin32 9 9	9.9	BMP6, JAK2, CDKN3, ITGAM, ITGB2, GSR
39	phosphoinositide32	7.8	PIK3C2A, NCF4, MYD88, SAG, JUN, JAK2
40	matrigel32	7.8	BMP6, JUN, JAK2, ITGA4, ITGB1, MMP9
41	ciglitazone32	7.5	JUN, MMP9, IL1B, IL6, IL8, APOE
42	cyclosporin a32 42	8.5	PIK3C2A, CIITA, SAG, JUN, JAK2, CD28
43	rantes32	7.3	MYD88, BMP6, CIITA, JUN, CD209, CD4
44	oxygen32 18	8.0	PIK3C2A, NCF2, NCF4, CIITA, MT-CYB, SAG
45	actinomycin d32	6.6	LPA, CIITA, JUN, JAK2, CDKN3, MMP9
46	dexamethasone32 42 34 9 9	10.3	BMP6, CIITA, JUN, JAK2, CD209, CD28
47	herbimycin a32 42	6.7	BMP6, JUN, JAK2, CD28, CD4, CDKN3
48	tyrosine32	5.2	PIK3C2A, NCF2, MYD88, BMP6, CIITA, SAG
49	cycloheximide32	5.1	LMLN, BMP6, CIITA, MT-CYB, JUN, JAK1
50	phosphatidylinositol32	5.0	PIK3C2A, NCF2, NCF4, MYD88, BMP6, CIITA

Cellular components related to leishmaniasis according to GeneDecks:

(show all 17)

id	Name	GO ID	Score	Top Affiliating Genes
1	integral to lumenal side of endoplasmic reticulum membrane	GO:071556	10.6	HLA-G, CALR, HLA-DPA1, HLA-DRB5, HLA-DRB4, HLA-DRB3
2	ER to Golgi transport vesicle membrane	GO:012507	10.5	HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-G, HLA-DRB1, HLA-DRA
3	clathrin-coated endocytic vesicle membrane	GO:030669	10.5	HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-DRA, HLA-DQB1
4	MHC class II protein complex	GO:042613	10.4	HLA-DRB4, HLA-DRB3, HLA-DRB1, HLA-DRA, HLA-DQB1, HLA-DQA2
5	trans-Golgi network membrane	GO:032588	10.4	HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-DRA, HLA-DQB1
6	transport vesicle membrane	GO:030658	10.4	HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-DRA, HLA-DQB1
7	endocytic vesicle membrane	GO:030666	10.3	HLA-DRB5, HLA-DRB4, HLA-DRB3, HLA-DRB1, HLA-DRA, HLA-DQB1
8	integral to plasma membrane	GO:005887	10.1	TNF, HLA-DRB4, HLA-DRB3, HLA-DRB1, HLA-DRA, TNFRSF1A
9	lysosomal membrane	GO:005765	10.0	HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, OCA2
10	extracellular space	GO:005615	10.0	CP, CST3, SOD1, CXCL9, PROC, DPEP1
11	external side of plasma membrane	GO:009897	10.0	IL17A, IL13, IL12RB1, FCGR3A, FCER2, ITGB1
12	late endosome membrane	GO:031902	9.9	SLC11A1, HLA-DRB5, HLA-DRB4, HLA-DRB3, HLA-DRB1, HLA-DRA
13	endosome membrane	GO:010008	9.7	HLA-DQA2, HLA-DQB1, TRAF6, TLR4, TF, TAB1
14	cell surface	GO:009986	9.5	TLR2, TGFB1, TGFB2, TGFB3, DPP4, CXCR2
15	extracellular region	GO:005576	9.4	TGFB1, CRP, TNFRSF1A, CALCA, ALB, F5
16	plasma membrane	GO:005886	8.1	HLA-DRB3, IFNGR2, IFNGR1, GPR132, GPI, CCR5
17	cytosol	GO:005829	5.8	SRM, ODC1, PNP, NOS2, RPL14, PTPN6

Biological processes related to leishmaniasis according to GeneDecks:

(show top 50)    (show all 99)

id	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of growth of symbiont in host	GO:044130	11.0	IFNG, IL10, MYD88, TNF, TLR2, IL12B
2	cellular response to lipopolysaccharide	GO:071222	10.8	TLR4, ARG1, IL12B, IL8, ICAM1, CCL2
3	negative regulation of T cell proliferation	GO:042130	10.7	FOXP3, IL10, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5
4	T cell costimulation	GO:031295	10.4	CD28, CD4, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2
5	antigen processing and presentation of exogenous peptide antigen via MHC class II	GO:019886	10.4	HLA-DPB1, HLA-DRB3, HLA-DRB1, HLA-DQB1, HLA-DQA2, HLA-DQA1
6	positive regulation of interleukin-17 production	GO:032740	10.4	MYD88, IL15, IL2, IL21, IL12B, TGFB1
7	positive regulation of T cell proliferation	GO:042102	10.3	IL12B, IL15, IL1B, IL21, IL4, IL6
8	positive regulation of inflammatory response	GO:050729	10.3	IL15, TNFRSF1A, IL21, IL2, JAK2, TLR2
9	T-helper 1 type immune response	GO:042088	10.3	HLA-DRB5, HLA-DRB3, HLA-DRB1, TLR4, TRAF6, HLA-DRB4
10	regulation of interferon-gamma-mediated signaling pathway	GO:060334	10.3	JAK1, JAK2, PTPN6, IFNG, IFNGR1, IFNGR2
11	interferon-gamma-mediated signaling pathway	GO:060333	10.2	JAK2, JAK1, CIITA, HLA-DPB1, HLA-DPA1, HLA-DQA1
12	negative regulation of interferon-gamma production	GO:032689	10.2	IL10, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, TLR4
13	positive regulation of interferon-gamma production	GO:032729	10.1	TLR4, IL12A, IL12B, IL1B, IL12RB1, IL2
14	immunoglobulin production involved in immunoglobulin mediated immune response	GO:002381	10.0	HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-DQB1
15	immune response	GO:006955	9.9	CTLA4, PNP, TLR2, TLR4, CXCL9, C3
16	cell surface receptor signaling pathway	GO:007166	9.8	CD28, CCL2, CCR5, IFNB1, IFNG, IFNGR2
17	positive regulation of interleukin-6 production	GO:032755	9.5	IL1B, MYD88, IL6, MAPK13, TNF, TLR2
18	positive regulation of nitric oxide biosynthetic process	GO:045429	9.4	TLR4, JAK2, IL1B, ICAM1, TNF, IFNG
19	platelet activation	GO:030168	9.4	TGFB2, SOD1, PRKCB, TF, TGFB3, APOA1
20	T cell receptor signaling pathway	GO:050852	9.3	HLA-DRB5, HLA-DRB4, TRAF6, CD4, NFKB1, NFKBIA
21	response to hypoxia	GO:001666	9.3	TNF, CAT, LONP1, FAS, IL1B, IL1A
22	cellular response to mechanical stimulus	GO:071260	9.2	TLR4, IL13, TNFRSF1A, MAPK3, IL1B, FAS
23	anti-apoptosis	GO:006916	9.1	RELA, NFKB1, IRAK1, TRAF6, SOD1, GLO1
24	aging	GO:007568	9.0	ADA, FAS, JUN, NCF2, IL1B, CCL2
25	positive regulation of smooth muscle cell proliferation	GO:048661	9.0	PTGS2, TRAF6, MYD88, STAT1, IRAK4, IL13
26	lipopolysaccharide-mediated signaling pathway	GO:031663	8.9	MAPK3, MAPK14, CCL2, TNF, NFKBIA, TLR2
27	inflammatory response	GO:006954	8.9	NFKB1, TLR2, TGFB1, CXCL9, CXCR1, CXCR2
28	response to drug	GO:042493	8.8	ABCB1, LTA, PNP, UQCRFS1, TOP1, TGFB1
29	positive regulation of I-kappaB kinase/NF-kappaB cascade	GO:043123	8.8	FASLG, IRAK1, PRKCB, TAB2, TLR4, TNFRSF1A
30	positive regulation of NF-kappaB transcription factor activity	GO:051092	8.8	NFKBIB, NFKBIA, NFKB1, TNFRSF8, TNF, TRAF6
31	activation of MAPK activity	GO:000187	8.8	SOD1, CXCR4, TAB2, TAB1, MAPK3, IRAK1
32	cytokine-mediated signaling pathway	GO:019221	8.7	HLA-DRB4, HLA-DRB5, HLA-G, TNFRSF1A, PTPN1, PTPN6
33	blood coagulation	GO:007596	8.7	ITGAM, PTPN6, NOS2, TGFB1, TGFB3, KIF2B
34	signal transduction	GO:007165	8.7	IL10RA, PRKCB, STMN1, TLR2, NFKBIB, TNFRSF8
35	positive regulation of apoptotic process	GO:043065	8.4	TLR4, TGFB2, SOD1, CTLA4, GZMA, MMP9
36	stress-activated MAPK cascade	GO:051403	8.4	MAPK14, MAP3K7, TAB1, TAB2, ELK1, TRAF6
37	response to lipopolysaccharide	GO:032496	8.1	PTGS2, TNFRSF1A, FAS, FASLG, IL1A, IL13
38	apoptotic process	GO:006915	7.7	PSMB1, MAPK14, MAP3K7, FAS, FASLG, IL1B
39	MyD88-independent toll-like receptor signaling pathway	GO:002756	7.7	JUN, FOS, IRAK1, MAP3K7, MAPK3, MAPK14
40	toll-like receptor 3 signaling pathway	GO:034138	7.5	TAB2, TAB1, TLR4, ELK1, NFKBIB, NFKBIA
41	TRIF-dependent toll-like receptor signaling pathway	GO:035666	7.5	NFKB1, TRAF6, MAPK1, MAPK11, MAPK14, MAPK3
42	negative regulation of cell proliferation	GO:008285	7.5	TNF, TNFRSF8, PTGS2, TGFB1, TGFB2, TGFB3
43	toll-like receptor 4 signaling pathway	GO:034142	7.4	TAB1, IRAK1, FOS, JUN, MYD88, RELA
44	Toll signaling pathway	GO:008063	7.4	MYD88, JUN, FOS, IRAK1, IRAK4, MAP3K7
45	toll-like receptor 2 signaling pathway	GO:034134	7.3	TLR4, TAB2, TAB1, MAPK14, MAPK3, MAP3K7
46	toll-like receptor 1 signaling pathway	GO:034130	7.3	NFKB1, TRAF6, MAPK1, MAPK11, MAPK14, MAPK3
47	MyD88-dependent toll-like receptor signaling pathway	GO:002755	7.3	MAPK14, TAB2, TAB1, MAPK11, MAPK1, TRAF6
48	positive regulation of transcription from RNA polymerase II promoter	GO:045944	7.3	IFNB1, STAT1, TGFB3, TGFB1, SLC11A1, IGF1
49	toll-like receptor signaling pathway	GO:002224	7.3	RELA, MYD88, JUN, FOS, IRAK1, IRAK4
50	innate immune response	GO:045087	6.5	TAB1, CYBA, TRAF6, IFNB1, MAPK1, MAPK11

Molecular functions related to leishmaniasis according to GeneDecks:

(show all 10)

id	Name	GO ID	Score	Top Affiliating Genes
1	MHC class II receptor activity	GO:032395	10.5	HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DQA1, HLA-DQA2, HLA-DQB1
2	cytokine activity	GO:005125	10.3	BMP6, IFNG, TNF, LTA, TGFB2, CXCL9
3	peptide antigen binding	GO:042605	10.3	CD209, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5
4	IgG binding	GO:019864	10.1	FCGR3B, FCGR3A, FCGR2C, FCGR2A, FCGR1A
5	growth factor activity	GO:008083	10.0	IL6, GPI, IGF1, TGFB1, TGFB2, TGFB3
6	receptor binding	GO:005102	9.8	HLA-G, NOS2, LTA, TGFB2, DPP4, C3
7	interleukin-12 receptor binding	GO:005143	9.8	IL12RB1, IL12B, IL12A, JAK2
8	MAP kinase activity	GO:004707	9.6	MAPK1, MAPK11, MAPK14, MAPK3, MAPK13, MAPK12
9	protein homodimerization activity	GO:042803	8.4	CRP, NOS2, NFKB1, G6PD, TGFB1, TGFB2
10	protein binding	GO:005515	3.7	CTLA4, DPEP1, DPP4, TF, TAB1, TAB2